Prostate Cancer Articles | Page 2

A Practice Model Designed to Reward Physician Partners Equally
Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.
In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.
Neoadjuvant Sonidegib Active in High-Risk Prostate Cancer
In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.
Sensitivity, Resistance of Molecular Subtypes in Prostate Cancer Identified Through Drug Response Scores
Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.
Radium-223/Abiraterone Phase III mCRPC Trial Unblinded
The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early.
MRI, PCA3 Tests Are Reliable Indicators of Prostate Biopsy Positivity
Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.
Radium-223 Retreatment Shows Promise in mCRPC
A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.
EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer
The European Commission has approved abiraterone acetate (Zytiga) in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.
Expert Shares Insight on Role of RT, Surgery in Prostate Cancer
Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.
LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
Publication Bottom Border
Border Publication